[go: up one dir, main page]

WO2010138184A2 - Anticorps d'origine aviaire - Google Patents

Anticorps d'origine aviaire Download PDF

Info

Publication number
WO2010138184A2
WO2010138184A2 PCT/US2010/001545 US2010001545W WO2010138184A2 WO 2010138184 A2 WO2010138184 A2 WO 2010138184A2 US 2010001545 W US2010001545 W US 2010001545W WO 2010138184 A2 WO2010138184 A2 WO 2010138184A2
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
composition
molecules
antibodies
antibody molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/001545
Other languages
English (en)
Other versions
WO2010138184A3 (fr
Inventor
Alex J. Harvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synageva Biopharma Corp
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Priority to EP10780931.1A priority Critical patent/EP2435476A4/fr
Publication of WO2010138184A2 publication Critical patent/WO2010138184A2/fr
Publication of WO2010138184A3 publication Critical patent/WO2010138184A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Definitions

  • anti-CD20 e.g., anti-CD20
  • a potential glycosylation site for an anti-CD20 antibody of the invention is shown in Figure 3.
  • the invention is not limited to glycosylation at any particular site of the anti-CD20 antibody.
  • compositions which contain isolated mixtures of an individual type of useful antibody molecule, such as those antibodies disclosed herein, where one or more of the antibody molecules contained in the mixture has a specific oligosaccharide structure attached, in particular, an oligosaccharide structure disclosed herein which may be produced by a transgenic avian.
  • Figure 3 shows the light chain (SEQ ID NO: 1) and heavy chain (SEQ ID NO: 2) amino acid sequences of anti-CD20 antibody made in accordance with the invention.
  • Figure 4 shows the amino acid sequence of a single chain anti-CD20 molecule (SEQ ID NO: 3) that can be produced in accordance with the invention.
  • Figure 5 shows a heavy chain (SEQ ID NO: 4) and light chain (SEQ ID NO: 5) of C2H7 antibody contemplated for production in accordance with the invention.
  • Figure 6 shows the CDC activity of the anti-CD20 produced in accordance with the invention as described in Examples 1 to 3 (filled triangle) compared to the same anti-CD20 antibody produced in CHO cells (filled diamond).
  • transformation all denote the introduction of a polynucleotide into a cell such as an avian cell.
  • the invention also includes compositions containing 15 antibodies of the invention, each having a different attached oligosaccharide structure selected from the group shown in Figures 1 and 2.
  • the invention also includes compositions containing 16 antibodies of the invention, each having a different attached oligosaccharide structure selected from the group shown in Figures 1 and 2.
  • the invention also includes compositions containing 17 antibodies of the invention, each having a different attached oligosaccharide structure selected from the group shown in Figures 1 and 2.
  • the invention also includes compositions containing 18 antibodies of the invention, each having a different attached oligosaccharide structure selected from the group shown in Figures 1 and 2.
  • the mixture of antibody molecules such as anti- CD20 molecules may contain one or more antibody molecules having an oligosaccharide pattern which is disclosed herein and is not present when produced in CHO cells plus one or more antibody molecules having an oligosaccharide pattern which could be obtained in mammalian cell production.
  • essentially none of the N-linked oligosaccharide structure types present on the antibody molecules (e.g., cytotoxic antibody molecules) such as anti-CD20 molecules of the invention contain fucose.
  • about 70% or more of the N-linked oligosaccharide structure types present on the antibody molecules (e.g., cytotoxic antibody molecules) such as anti-CD20 molecules of the invention do not contain fucose.
  • about 75% or more of the N- linked oligosaccharide structure types present on the antibody molecules (e.g., cytotoxic antibody molecules) such as anti-CD20 molecules of the invention do not contain fucose.
  • the N-linked oligosaccharide structure types present on the antibody molecules such as anti-CD20 molecules of the invention contain a bisecting GIcNAc.
  • about 5% or more of the N-linked oligosaccharide structure types present on the antibody molecules (e.g., cytotoxic antibody molecules) such as anti-CD20 molecules of the invention contain a bisecting GIcNAc.
  • about 10% or more of the N-linked oligosaccharide structure types present on the antibody molecules (e.g., cytotoxic antibody molecules) such as anti-CD20 molecules of the invention contain a bisecting GIcNAc.
  • N-linked oligosaccharide structure types present on the antibody molecules e.g., cytotoxic antibody molecules
  • the N-linked oligosaccharide structure types present on the antibody molecules are terminated partially or exclusively with N-acetyl glucosamine.
  • about 60% or more of the N-linked oligosaccharide structure types present on the antibody molecules (e.g., cytotoxic antibody molecules) such as anti-CD20 molecules of the invention are terminated partially or exclusively with N-acetyl glucosamine.
  • the antibody molecules such as anti-CD20 molecules of the invention have a glycosylation pattern resulting from the molecules being produced in an oviduct cell of an avian.
  • Another aspect of the invention relates to compositions containing antibody molecules (e.g., cytotoxic antibody molecules) such as anti-CD20 molecules produced in an avian oviduct cell (e.g., a tubular gland cell) that have a glycosylation pattern other than that of antibody molecules produced in a mammalian cell such as a CHO cell.
  • compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution; as a suspension; or as an emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
  • the tablets may be coated according to methods well known in the art.
  • Protein therapeutics which can be produced in accordance with the invention include, without limitation, Factor VIII; B-domain deleted Factor VIII; Factor Vila; Factor IX; anticoagulant; recombinant hirudin; anticoagulant; recombinant hirudin; Alteplase, tPA; Reteplase, human tPA - 3 of 5 domains deleted; Factor XI; Factor XII (Hageman factor); Factor XIII; Alpha2-antiplasmin; Microplasmin; insulin lispro; Bio Lysprol, an insulin analog; insulin aspart; insulin glargine; long-acting insulin analog; hGH; glucagons; TSH; follitropin-beta FSH; salmon calcitonin; (Teriparatide) Parathyroid hormone derivative; nesiritide, B-type natriuretic peptide (BNP); PDGH; Lutropin alfa; Choriogonadotropin alf
  • VITAXINTM which is a humanized anti- ⁇ V ⁇ 3 integrin antibody
  • LYMPHOCIDETM which is a humanized anti-CD22 IgG antibody (Immunomedics);
  • MALDI-TOF-MS Microx assisted laser desorption ionization time-of-flight mass spectrometry
  • ESI MS/MS electrospray ionization tandem mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention englobe, entre autres choses, des anticorps comprenant des anticorps cytotoxiques tels que anti-CD20 ayant des motifs de glycosylation à liaison N aviaire obtenus à partir de blanc d'œuf d'œufs pondus par des oiseaux transgéniques.
PCT/US2010/001545 2009-05-27 2010-05-27 Anticorps d'origine aviaire Ceased WO2010138184A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10780931.1A EP2435476A4 (fr) 2009-05-27 2010-05-27 Anticorps d'origine aviaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21713809P 2009-05-27 2009-05-27
US61/217,138 2009-05-27

Publications (2)

Publication Number Publication Date
WO2010138184A2 true WO2010138184A2 (fr) 2010-12-02
WO2010138184A3 WO2010138184A3 (fr) 2011-04-21

Family

ID=43220484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001545 Ceased WO2010138184A2 (fr) 2009-05-27 2010-05-27 Anticorps d'origine aviaire

Country Status (3)

Country Link
US (2) US8815242B2 (fr)
EP (1) EP2435476A4 (fr)
WO (1) WO2010138184A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161940A1 (fr) * 2013-04-04 2014-10-09 Mabxience S.A. Procédé d'augmentation de la formation d'acide pyro-glutamique d'une protéine
JP2014532074A (ja) * 2011-10-19 2014-12-04 エフィムネ ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2406402B1 (fr) * 2009-03-13 2018-05-16 Cornell University Procédé pour évaluer un état d'allogreffe humaine à partir des taux d'expression de micro-arn
US9746479B2 (en) 2010-03-09 2017-08-29 Cornell University Methods and compositions to predict and detect acute rejection
HUE035281T2 (en) 2011-01-14 2018-05-02 Univ California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2015105938A1 (fr) * 2014-01-08 2015-07-16 World Biotechnology LLC Organismes génétiquement modifiés pour produire des composés organiques
CN108690138A (zh) * 2017-04-12 2018-10-23 鸿运华宁（杭州）生物医药有限公司 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677180A (en) 1987-01-08 1997-10-14 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US20070077650A1 (en) 2005-10-05 2007-04-05 Avigenics, Inc. Rapid production of high titer virus
US7338654B2 (en) 1997-10-16 2008-03-04 Avigenics, Inc. Glycosylated interferon alpha obtained from a transgenic chicken
US20080064862A1 (en) 2004-12-29 2008-03-13 Avigenics, Inc. Transgene expression in a avians
US7381560B2 (en) 1992-11-13 2008-06-03 Biogen Idec Inc. Expression and use of anti-CD20 antibodies
WO2008142124A1 (fr) 2007-05-21 2008-11-27 Vivalis Production de protéines recombinantes dans des cellules aviaires ebx®
US20090074718A1 (en) 1997-10-16 2009-03-19 Ivarie Robert D Avian derived erythropoietin
US7511120B2 (en) 1997-10-16 2009-03-31 Synageva Biopharma Corp. Glycosylated G-CSF obtained from a transgenic chicken

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
GB8714426D0 (en) * 1987-06-19 1987-07-22 Agricultural & Food Res Culture technique
US4997763A (en) * 1987-07-31 1991-03-05 The United States Of America As Represented By The Secretary Of Agriculture Vectors for gene insertion into avian germ line
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
WO1993014629A1 (fr) * 1992-01-27 1993-08-05 North Carolina State University Transfert de genes chez des oiseaux par introduction d'adn dans les muscles in ovo
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US6825396B2 (en) * 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6861572B1 (en) * 1997-11-14 2005-03-01 Origen Therapeutics, Inc. Production of proteins in eggs
US20050114916A1 (en) * 1998-08-21 2005-05-26 Etches Robert J. Production of proteins in eggs
WO1999019472A1 (fr) * 1997-10-16 1999-04-22 University Of Georgia Research Foundation, Inc. Vecteurs comprenant un promoteur specifique du tube albuminipare, pour la transgenese aviaire
US20040019923A1 (en) * 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
US20040136986A1 (en) * 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es) * 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
ATE339507T1 (de) * 1998-06-15 2006-10-15 Gtc Biotherapeutics Inc Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US6897044B1 (en) * 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP3031917A1 (fr) * 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité d'une molécule immunologiquement fonctionnelle
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US20060034828A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US20060024304A1 (en) * 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US7625756B2 (en) * 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
AU7684201A (en) * 2000-06-28 2002-01-08 Glycofi Inc Methods for producing modified glycoproteins
US20060034830A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
CA2411968C (fr) * 2000-06-30 2009-12-15 Flanders Interuniversity Institute For Biotechnology (Vib) Modification de glycosylation de proteine dans pichia pastoris
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US20060025739A1 (en) * 2003-12-30 2006-02-02 Dipalma Joseph Wrapper component for personal care articles having a sensory cue for opening
NZ545176A (en) * 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
WO2003011878A2 (fr) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
WO2003025146A2 (fr) * 2001-09-18 2003-03-27 Avigenics, Inc. Production d'oiseaux transgeniques par injection cytoplasmique
BR0213761A (pt) * 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
US7335761B2 (en) * 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20060024292A1 (en) * 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060191026A1 (en) * 2005-02-18 2006-08-24 Origen Therapeutics, Inc. Tissue specific expression of antibodies in chickens
US7323618B2 (en) * 2002-02-01 2008-01-29 Origen Therapeutics, Inc. Tissue specific expression of exogenous proteins in transgenic chickens
US7145057B2 (en) * 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
EP1519959B1 (fr) * 2002-02-14 2014-04-02 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
US20030182675A1 (en) * 2002-03-22 2003-09-25 Origen Therapeutics Functional disruption of avian immunoglobulin genes
WO2003085107A1 (fr) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
WO2003084569A1 (fr) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
EP1500698B1 (fr) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
IL165717A0 (en) * 2002-06-26 2006-01-15 Flanders Interuniversity Inst A strain of methylotrophic yeast for producing proteins
HU227217B1 (en) * 2002-12-16 2010-11-29 Genentech Inc Immunoglobulin variants and uses thereof
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
EP1633781A2 (fr) 2003-06-06 2006-03-15 Avigenics, Inc. Promoteurs ovomucoides et procedes d'utilisation
US20060021071A1 (en) * 2003-10-09 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Cell in which genome is modified
WO2005035740A1 (fr) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Cellule modifiee par genome neutralisee jusqu'a obtention d'un systeme exempt de serum
JP4069867B2 (ja) * 2004-01-05 2008-04-02 セイコーエプソン株式会社 部材の接合方法
AR049021A1 (es) * 2004-04-16 2006-06-21 Genentech Inc Tratamiento de trastornos con un anticuerpo que se une a cd20
WO2005117972A2 (fr) 2004-05-05 2005-12-15 Genentech, Inc. Prevention d'une maladie auto-immune
AU2005251764A1 (en) * 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
DOP2006000013A (es) * 2005-01-13 2006-07-15 Genentech Inc Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
AU2006210645A1 (en) 2005-02-01 2006-08-10 Symphogen A/S Transgenic chickens
EP1865058B1 (fr) 2005-03-31 2011-01-12 Biomedics Inc. Anticorps monoclonal anti-cd-20
WO2007039818A2 (fr) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc
US20070110282A1 (en) * 2005-06-23 2007-05-17 Millsapp Deena L Protecting social security numbers from identity theft
US20070015127A1 (en) * 2005-07-18 2007-01-18 Glen Teyf Method of mental training
AR055137A1 (es) * 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
US20070092486A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
WO2009142186A1 (fr) * 2008-05-20 2009-11-26 株式会社カネカ Composition cytotoxique

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677180A (en) 1987-01-08 1997-10-14 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7381560B2 (en) 1992-11-13 2008-06-03 Biogen Idec Inc. Expression and use of anti-CD20 antibodies
US7422739B2 (en) 1992-11-13 2008-09-09 Biogen Idec Inc. Anti-CD20 antibodies
US7338654B2 (en) 1997-10-16 2008-03-04 Avigenics, Inc. Glycosylated interferon alpha obtained from a transgenic chicken
US20090074718A1 (en) 1997-10-16 2009-03-19 Ivarie Robert D Avian derived erythropoietin
US7511120B2 (en) 1997-10-16 2009-03-31 Synageva Biopharma Corp. Glycosylated G-CSF obtained from a transgenic chicken
US20080064862A1 (en) 2004-12-29 2008-03-13 Avigenics, Inc. Transgene expression in a avians
US20070077650A1 (en) 2005-10-05 2007-04-05 Avigenics, Inc. Rapid production of high titer virus
WO2008142124A1 (fr) 2007-05-21 2008-11-27 Vivalis Production de protéines recombinantes dans des cellules aviaires ebx®

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDERSON, R. A.; SANDO, G. N.: "Cloning and Expression of cDNA Encoding Human Lysosomal Acid Lipase/Cholesteryl Ester Hydrolase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 33, 25 November 1991 (1991-11-25), pages 22479 - 22484, XP002192752
LEE ET AL., MOLECULAR IMMUNOLOGY, vol. 36, 1999, pages 61 - 71
SAMBROOK; FRITSCH; MANIATIS: "Molecular Cloning, a Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY
See also references of EP2435476A4
SORGE ET AL.: "Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA", PROC. NATL. ACAD. SCI, vol. 82, 1985, pages 7289 - 7293, XP001038214, DOI: doi:10.1073/pnas.82.21.7289
ZHU ET AL., NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1159 - 1169

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532074A (ja) * 2011-10-19 2014-12-04 エフィムネ ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用
WO2014161940A1 (fr) * 2013-04-04 2014-10-09 Mabxience S.A. Procédé d'augmentation de la formation d'acide pyro-glutamique d'une protéine
CN105121469A (zh) * 2013-04-04 2015-12-02 麦布西恩斯公司 用于增加蛋白质的焦谷氨酸形成的方法
AU2014247034B2 (en) * 2013-04-04 2018-08-23 Mabxience S.A. A method for increasing pyro-glutamic acid formation of a protein
US10400042B2 (en) 2013-04-04 2019-09-03 Mabxience Research, S.L. Method for increasing pyro-glutamic acid formation of a protein

Also Published As

Publication number Publication date
WO2010138184A3 (fr) 2011-04-21
US8815242B2 (en) 2014-08-26
US20100303806A1 (en) 2010-12-02
US20140336362A1 (en) 2014-11-13
EP2435476A4 (fr) 2013-04-17
EP2435476A2 (fr) 2012-04-04

Similar Documents

Publication Publication Date Title
US20140336362A1 (en) Avian Derived Antibodies
AU2009204495B2 (en) Glycosylation in avians
US8124732B2 (en) Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US20080124792A1 (en) Hybrid promoters
EP1931698B1 (fr) Production rapide d'un virus de titre eleve
WO2008057161A1 (fr) Érythropoiétine dérivée des oiseaux
US10577612B1 (en) Compositions and methods relating to genomic modifications in avian primordial germ cells
US20090074718A1 (en) Avian derived erythropoietin
US20090105462A1 (en) Glycosylated erythropoietin
US20090099067A1 (en) Glycosylated G-CSF
WO2007108882A2 (fr) G-csf glycosylé
US20140298503A1 (en) Glycosylation in Avians
CN101595125A (zh) 禽类衍生的红细胞生成素
US7795496B2 (en) In vivo transfection in avians
CN101405299A (zh) 糖基化的g-csf

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10780931

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010780931

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010780931

Country of ref document: EP